Drug Details
| General Information of the Drug (ID: DR9241) | ||||
|---|---|---|---|---|
| Name |
Gentamicin
|
|||
| Synonyms |
gentamicin; Gentavet; Gentamicins; GENTAMYCIN; Gentamicin sulphate sterile; Gentacycol; 1403-66-3; Cidomycin; Gentamicinum; Gentamycinum; Refobacin; Garasol; Refobacin TM; Gentamicina; Gentamicine; Gentocin; Gentamycin-creme; Gentamycins; Gentamicine [INN-French]; Gentamicinum [INN-Latin]; Gentamycin-creme [German]; Gentamicina [INN-Spanish]; Oksitselanim; Centicin; Lyramycin; Septigen; Gentamicin (TN); Gentamicin (BAN); Gentamicin [INN]; HSDB 3087; Gentamicin [INN:BAN]; EINECS 215-765-8; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside; SCHEMBL537630; CHEMBL329592; GTPL2427; SCHEMBL19996168; STL454325; AKOS015961211; DB00798; J4.074F; 2-[4,6-diamino-3-[3-amino-6-(1-methylaminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-methylaminooxane-3,5-diol; AC-13386; FT-0626646; FT-0668965; D08013; 123871-EP2292088A1; 123871-EP2295422A2; 123871-EP2295439A1; Q422482
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Clearance
The drug present in the plasma can be removed from the body at the rate of 1 mL/min/kg
Elimination
In patients with normal renal function, 70% or more of an initial gentamicin dose can be recovered in the urine within 24 hours
Half-life
The concentration or amount of drug in body reduced by one-half in 75 minutes (after intravenous administration)
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.28133 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 1%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.33 L/kg
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C21H43N5O7
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
|
|||
| InChI |
1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3
|
|||
| InChIKey |
CEAZRRDELHUEMR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1403-66-3
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Acteoside | Cistanche | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
| Escherichia coli | Microorganism model | Escherichia coli | ||||
| Experimental
Result(s) |
The co-administration of verbascoside and gentamicin was more effective and synergistic activities (FICI<1) against clinical isolates. | |||||
| Apalcillin | Escherichia coli | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | For a xenograft model, mice were made neutropenic by intraperitoneal (ip) injection of cyclophosphamide at a dose of 100 mg/kg on days 0, 2,4. | |||||
| Experimental
Result(s) |
Apalcillin when combined with gentamicin is effective in treating serious P. aeruginosa bacteraemia in neutropenic mice. | |||||
| Bisdemethoxycurcumin | Curcumin | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | UL54 | Molecule Info | ||
| In-vitro Model | Staphylococcus aureus strains | Microorganism model | Staphylococcus aureus | |||
| Experimental
Result(s) |
Antimicrobial effect of BDMC combined with antibiotics was superior to treatment with that of a single agent alone. | |||||
| Pannarin | Pannaria tavaresii | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
| Experimental
Result(s) |
The natural compound pannarin might be a good candidate for the individualization of novel templates for the development of new antimicrobial agents or combinations of drugs for chemotherapy. | |||||
| Plumbagin | Plumbago europaea | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Klebsiella pneumoniae | Microorganism model | Klebsiella pneumoniae | |||
| Experimental
Result(s) |
Herbal compound plumbagin was identified to stimulate gentamicin uptake by CRKp via enhancing TCA efflux and PMF to achieve a synergistic antibacterial effect. Plumbagin may be used in combination with aminoglycosides for severe CRKp infection by potentiating their therapeutic efficacy and lowering dosage. | |||||
| 1,8-cineole + Clavulanate | Click to Show/Hide the Molecular Data of This NP | |||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
| Susceptible Saureus | Microorganism model | Susceptible Saureus | ||||
| In-vivo Model | Forty-two female New Zealand white rabbits were used as animal model in this study. | |||||
| Experimental
Result(s) |
1,8-cineole showed a synergistic effect in combination with both AMC and gentamicin, which offer possibilities for reducing antibiotic usage. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Alpha linolenic acid | Perilla frutescens | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Eight-week-old balb/c albino male mice were used in this study. | |||||
| Experimental
Result(s) |
The gentamicin administration causes nephrotoxicity and the use of alpha-linolenic acid can be helpful against this toxic effect. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Bacterial 30S ribosomal RNA (Bact 30S rRNA) | Molecule Info | [9] | |